Floatz logo

Avova-1

Fallopian Tube Carcinoma

Aivita Biomedical, Inc.Cell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
The Netherlands Cancer Institute
Phase 3BB
Inno-206
Advenchen Laboratories, LLC
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Avova-1 is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →